Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry

• Published in: Journal of clinical pharmacology Vol. 61; no. 8; p. 1035
• Main Authors: Al-Kofahi, Mahmoud, Oetting, William S, Schladt, David P, Remmel, Rory P, Guan, Weihua, Wu, Baolin, Dorr, Casey R, Mannon, Roslyn B, Matas, Arthur J, Israni, Ajay K, Jacobson, Pamala A
• Format: Journal Article
• Language: English
• Published: England 01.08.2021
• Subjects: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Comorbidity; Cytochrome P-450 CYP3A - genetics; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - pharmacokinetics; Kidney Transplantation; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Tacrolimus - administration & dosage; Tacrolimus - pharmacokinetics; Transplant Recipients; White People; Young Adult; kidney transplant; genomics; pharmacogenomics; tacrolimus; population pharmacokinetics
• DOI: 10.1002/jcph.1823

Genetic variation in the CYP3A4 and CYP3A5 (CYP3A4/5) genes, which encode the key enzymes in tacrolimus metabolism, is associated with tacrolimus clearance and dose requirements. Tacrolimus has a narrow therapeutic index with high intra- and intersubject variability, in part because of genetic variation. High tacrolimus clearance and low trough concentration are associated with a greater risk for rejection, whereas high troughs are associated with calcineurin-induced toxicity. The objective of this study was to develop a model of tacrolimus clearance with a dosing equation accounting for genotypes and clinical factors in adult kidney transplant recipients of European ancestry that could preemptively guide dosing. Recipients receiving immediate-release tacrolimus for maintenance immunosuppression from 2 multicenter studies were included. Participants in the GEN03 study were used for tacrolimus model development (n = 608 recipients) and was validated by prediction performance in the DeKAF Genomics study (n = 1361 recipients). Nonlinear mixed-effects modeling was used to develop the apparent oral tacrolimus clearance (CL/F) model. CYP3A4/5 genotypes and clinical covariates were tested for their influence on CL/F. The predictive performance of the model was determined by assessing the bias (median prediction error [ME] and median percentage error [MPE]) and the precision (root median squared error [RMSE]) of the model. CYP3A5*3, CYP3A4*22, corticosteroids, calcium channel blocker and antiviral drug use, age, and diabetes significantly contributed to the interindividual variability of oral tacrolimus apparent clearance. The bias (ME, MPE) and precision (RMSE) of the final model was good, 0.49 ng/mL, 6.5%, and 3.09 ng/mL, respectively. Prospective testing of this equation is warranted.